Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01222689 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: selumetinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)